Patients with H pyloriindependent MALT lymphoma are curable with radiotherapy

Oncology

Volumn 25, Issue 12, 2011, Pages

  Yahalom, Joachim ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; RITUXIMAB;

CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER RESEARCH; CANCER SURVIVAL; DISEASE FREE SURVIVAL; ERADICATION THERAPY; GASTRECTOMY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MEDICAL DECISION MAKING; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIOSENSITIVITY; REVIEW; STOMACH LYMPHOMA; TREATMENT CONTRAINDICATION; WATCHFUL WAITING;

EID: 80855153793     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (6)

1. Goda JS, Gospodarowicz M, Pintillie M, et al. Long-term outcome in localized extranodal mucosa-associated lymphoid tissue lymphomas treated with radiotherapy. Cancer. 2010;116:3815-24.
2. NCCN lymphoma guideline version 2.2011. Available from: http://www.nccn.org.
3. Yahalom J. MALT lymphomas: a radiation oncology viewpoint. Ann Hematol. 2001;80(Suppl 3):B100-5. (updated for International Extranodal Lymphoma Study Group, 2010 (http://www.ielsg.org)
4. Haas RL, Poortmans P, de Jong D, et al. High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. J Clin Oncol. 2003;21:2474-80.
5. Conconi A, Martinelli G, Thielemont C, et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type. Blood. 2003;102:2741-5.
6. Zucca E, Conconi A, Pedrinis E, et al. Nongastric marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue. Blood. 2003;101:2489-95.